In addition to the analyses of the dynamic changes in the immune composition of chronic inflammation on reflux esophagitis and the tumor microenvironment of EC using the rat surgical carcinogenesis model, we examined the immunomodulating effect of metformin, which shows inhibitory activity against STAT3. The gene discussed is STAT3; the disease is gastroesophageal reflux disease.